BDA-366 |
カタログ番号GC10721 |
BDA-366 は強力な Bcl2 アンタゴニスト (Ki = 3.3 nM) であり、高い親和性と選択性で Bcl2-BH4 ドメインに結合します。 BDA-366 は、Bcl2 のコンフォメーション変化を誘発し、その抗アポトーシス機能を無効にし、生存分子から細胞死誘導因子に変換します。 BDA-366は肺がん細胞の増殖を抑制します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1909226-00-1
Sample solution is provided at 25 µL, 10mM.
BDA-366 is a selective antagonist of BCL2 BH4 domain with Ki value of 3.3 nM [1].
BCL2 is an important anti-apoptotic protein. BCL2 homology 4 (BH4) domain is required for its antiapoptotic function, thus acts as a promising anticancer target [1].
BDA-366 is a selective BCL2 inhibitor. BDA-366 induced conformational change of BCL2 that exposed the BH3 domain, resulting in abrogation of its prosurvival function and conversion of BCL2 to a prodeath protein. In non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells, BDA-366 selectively bound to BCL2 with high affinity. BDA-366 induced apoptosis by BCL2-dependent BAX activation and cytochrome c release. In H460 cells, BDA-366 reduced Bcl2/IP3R binding, which then increased Ca2+ release [1].
In mice bearing H460 lung cancer xenografts, treatment with BDA-366 (0, 10, 20, and 30 mg/kg/day) via i.p. route for 14 days induced apoptosis and potently inhibited tumor growth in a dose-dependent way. There was no significant toxicity at the maximum therapeutic dose. In tumor tissue from patients with NSCLC, BDA-366 synergized with RAD001 and resulted in significantly greater inhibition of lung cancer growth compared with either agent alone [1].
Reference:
[1]. Han B, Park D, Li R, et al. Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy. Cancer Cell, 2015, 27(6): 852-863.
Average Rating: 5
(Based on Reviews and 6 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *